47,742 Shares in Pfizer Inc. (NYSE:PFE) Purchased by CWA Asset Management Group LLC

CWA Asset Management Group LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 47,742 shares of the biopharmaceutical company's stock, valued at approximately $1,382,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $315,000. GSA Capital Partners LLP bought a new stake in Pfizer in the 1st quarter valued at $439,000. Duality Advisers LP acquired a new position in shares of Pfizer in the 1st quarter valued at $1,009,000. Atomi Financial Group Inc. lifted its holdings in shares of Pfizer by 103.4% during the 1st quarter. Atomi Financial Group Inc. now owns 37,422 shares of the biopharmaceutical company's stock worth $1,038,000 after acquiring an additional 19,024 shares during the period. Finally, Stonebrook Private Inc. acquired a new stake in shares of Pfizer during the 1st quarter valued at about $229,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 1.2 %

PFE stock traded down $0.32 during trading on Friday, hitting $26.72. The company had a trading volume of 55,951,315 shares, compared to its average volume of 38,136,520. The stock has a market cap of $151.42 billion, a price-to-earnings ratio of 36.11, a PEG ratio of 0.85 and a beta of 0.67. The company has a quick ratio of 0.60, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a 50-day moving average price of $28.89 and a 200-day moving average price of $28.65. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm's revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. As a group, analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.29%. Pfizer's dividend payout ratio is currently 227.03%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PFE. Daiwa Capital Markets upgraded shares of Pfizer from a "neutral" rating to an "outperform" rating and raised their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reiterated an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Citigroup initiated coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a "neutral" rating and a $30.00 target price on the stock. Finally, Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a "market perform" rating and a $32.00 target price for the company. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $33.58.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of the business's stock in a transaction dated Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.06% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.